MAIA Biotechnology (NYSEAMERICAN:MAIA) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

MAIA Biotechnology (NYSEAMERICAN:MAIA) released its quarterly earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01, FiscalAI reports.

MAIA Biotechnology Stock Performance

Shares of MAIA Biotechnology stock traded up $0.03 during mid-day trading on Monday, hitting $1.09. 226,201 shares of the stock were exchanged, compared to its average volume of 722,915. MAIA Biotechnology has a 12 month low of $0.87 and a 12 month high of $3.19. The company has a 50-day simple moving average of $1.21 and a 200 day simple moving average of $1.45. The company has a market capitalization of $67.30 million, a P/E ratio of -1.76 and a beta of 0.28.

Insider Buying and Selling

In other MAIA Biotechnology news, Director Ramiro Guerrero bought 78,239 shares of MAIA Biotechnology stock in a transaction dated Thursday, August 27th. The stock was bought at an average cost of $1.39 per share, with a total value of $108,752.21. Following the completion of the acquisition, the director directly owned 689,081 shares in the company, valued at approximately $957,822.59. The trade was a 12.81% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Vlad Vitoc purchased 73,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were acquired at an average cost of $1.37 per share, with a total value of $100,010.00. Following the completion of the transaction, the chief executive officer directly owned 1,049,121 shares of the company’s stock, valued at $1,437,295.77. The trade was a 7.48% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 258,078 shares of company stock worth $352,426 in the last 90 days. Company insiders own 19.81% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies. The company’s research is centered on treatments designed to address telomere biology, a process that plays an important role in the growth and survival of cancer cells.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine, a telomere-targeting agent intended to selectively affect cancer cells. The company has been evaluating THIO in combination with immune checkpoint inhibitors for patients with advanced or metastatic non-small cell lung cancer, including through its THIO-101 clinical program.

MAIA Biotechnology is headquartered in Chicago and is led by Chief Executive Officer Vlad Vitoc, M.D.